AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Harmony Biosciences Inc. (HRMY)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

34.78

-0.54 (-1.53%)

At close: Feb 20, 2025, 3:59 PM

35.84

3.05%

After-hours: Feb 20, 2025, 06:56 PM EST

undefined% (undefined)

Bid	33.5
Market Cap	1.98B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	2.11
PE Ratio (ttm)	16.48
Forward PE	n/a
Analyst	Buy

Ask	38
Volume	676,808
Avg. Volume (20D)	546,738
Open	35.15
Previous Close	35.32
Day's Range	34.28 - 35.41
52-Week Range	28.14 - 41.61
Beta	undefined

About HRMY

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmo...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Aug 19, 2020

Employees 246

Stock Exchange NASDAQ

Ticker Symbol HRMY

Website https://www.harmonybiosciences.com

Full Company Profile

Analyst Forecast

According to 9 analyst ratings, the average rating for HRMY stock is "Buy." The 12-month stock price forecast is $52.5, which is an increase of 50.95% from the latest price.

Buy 88.89%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Harmony Biosciences Inc. is scheduled to release its earnings on Feb 25, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 day ago New

-9.64%

Harmony Biosciences shares are trading lower after... Unlock content with Pro Subscription

3 months ago

-18.53%

Harmony Biosciences shares are trading lower after the company announced a public offering of up to 8 million shares of common stock by selling shareholders Marshman Fund Trust II and Valor IV Pharma Holdings.

News

1 day ago · benzinga.com

Harmony Biosciences Stock Falls On FDA Setback For Pitolisant In Sleeping Disorder

On Wednesday, Harmony Biosciences Holdings, Inc. HRMY received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for pitolisant for excessive daytime sleepiness (EDS) in ...

1 day ago · businesswire.com

Harmony Biosciences Provides Update on the Status of the Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FD...

3 days ago · zacks.com

HRMY or ONC: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and BeiGene, Ltd. (ONC). But which of these two stocks is ...

1 week ago · zacks.com

Here is Why Growth Investors Should Buy Harmony Biosciences (HRMY) Now

Harmony Biosciences (HRMY) is well positioned to outperform the market, as it exhibits above-average growth in financials.

2 weeks ago · zacks.com

Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

2 weeks ago · zacks.com

Wall Street Analysts Predict a 28.98% Upside in Harmony Biosciences (HRMY): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 29% in Harmony Biosciences (HRMY). While the effectiveness of this highly sought-after metric is questionable, ...

3 weeks ago · zacks.com

HRMY vs. RGEN: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and Repligen (RGEN). But which of these two stocks present...

4 weeks ago · seekingalpha.com

Harmony Biosciences: Don't Sleep On This Enterprising, Profitable Biotech

Harmony Biosciences Holdings, Inc.'s Wakix, a first-in-class drug for narcolepsy, has shown strong revenue growth and recent label expansion to pediatric patients, with good future growth potential. D...

4 weeks ago · zacks.com

4 High Earnings Yield Value Stocks to Buy as Trump Resumes Presidency

Unlock your portfolio value with high earnings yield value stocks like HRMY, NGVT, GPOR and PBI.

1 month ago · zacks.com

Should Value Investors Buy Harmony Biosciences (HRMY) Stock?

Load More News